Youcare Pharmaceutical Group (688658.SH) subsidiary YKYY033 injection has received FDA clinical trial approval.

Youcare Pharmaceutical Group (688658.SH) announced that its subsidiary, Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd., recently received a letter from the U.S. Food and Drug Administration (FDA) granting approval for the clinical trial application of YKYY033 injection for the prevention and treatment of venous and arterial thrombosis. It is reported that the product has already received clinical trial approvals for multiple anticoagulant-related indications from the National Medical Products Administration (NMPA) in June and July 2026, and the Phase I clinical study is progressing steadily. The successful receipt of the clinical trial permit from the U.S. FDA marks the product's formal qualification for overseas clinical development. Leveraging the approved comprehensive thrombosis prevention and treatment indication matrix, the company will conduct differentiated clinical explorations across multiple indications, precisely aligning with global mainstream anticoagulant treatment guidelines and clinical standards, helping to fill the market gap for highly safe, long-acting nucleic acid-based anticoagulants both globally and domestically.